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Intrauterine growth retardation (IUGR), the most important cause of perinatal mortality and morbidity, is deﬁned as a foetal
growth less than normal for the population, often used as synonym of small for gestational age (SGA). Studies demonstrated the
relationships between metabolic syndrome (MS) and birthweight. This study suggested that, in children, adolescents, and adults
born SGA, insulin resistance could lead to other metabolic disorders: type 2 diabetes (DM2), dyslipidemia, and nonalcoholic fatty
liver disease (NAFLD). NAFLD may evolve to nonalcoholic steatohepatitis (NASH), and it is related to the development of MS.
Lifestyle intervention, physical activity, and weight reduction represent the mainstay of NAFLD therapy. In particular, a catch-up
growth reduction could decrease the risk to develop MS and NAFLD. In this paper, we outline clinical and experimental evidences
of the association between IUGR, metabolic syndrome, insulin resistance, and NAFLD and discuss on a possible management to
avoid the risk of MS in adulthood.
1.Introduction
Intrauterine growth retardation (IUGR) is one of the most
important causes of perinatal mortality and morbidity and
aﬀects approximately 7–15% of worldwide pregnancies [1].
IUGR is commonly deﬁned as foetal growth less than that
characterizing commonly healthy population. However, to
date, there is no a clear internationally conventional clinical
deﬁnition for this term. In fact, although some studies use
IUGRassynonymofsmallforgestationalage(SGA),itisim-
portant to remember that infants born with IUGR may or
may not be necessarily SGA and, similarly, infants who are
SGA may be born without growth-restricting processes char-
acterizing IUGR [2, 3].
Although several causes or risk factors have been sug-
gested for development of IUGR, including those of mater-
nal, placental, and foetus origin [4], it is very diﬃcult to esta-
blish, in most situations, the real cause of this condition.
Inadditiontothehighratesofperinatalmortality,IUGR,
recently, has been often associated with the development of
several features of metabolic syndrome (MS) in adulthood,
increasingseriouslytheriskofmortalityassociatedtocardio-
vascular disease [5]. Features of MS classically associated
with IUGR are insulin resistance, hypertension, dyslipide-
mia, impaired glucose tolerance, and type 2 diabetes (DM2);
but, very recently, also nonalcoholic fatty liver disease
(NAFLD) has been included among the persistent IUGR-de-
pendent metabolic dysfunctions [6, 7].
Furthermore, on the basis of numerous pieces of eviden-
cesdemonstratingthatearlyimprovementingrowthappears
beneﬁcial for a number of important outcomes, the person-
nel of neonatal follow-up clinics are encouraged to promote
early catch-up growth for SGA subjects [8]. However, from
2003, several controversial studies have forwarded the hypo-
thesis that restricting postnatal catchup after prematurity
could prevent later metabolic abnormalities [9].
Inthispaper,weoverviewonseveralaspectsassociatedto
IUGR, discussing with a particular attention all correlation
with MS and NAFLD. In addition, here, we emphasize on the
fact that an optimal nutritional management needs to achi-
evenormalgrowthvariablesandanormalbodycomposition
without increasing the risk of MS in adulthood.2 International Journal of Endocrinology
2. Concepts of IUGRandSGA
IUGR and SGA are related but not synonymous, although
both the terms are used interchangeably and both denote
malnutrition.
IUGRisaclinicalconditionthatoccurswhentheunborn
baby is at or below the 10th weight percentile for his or her
age (in weeks). The foetus is aﬀected by a pathologic restric-
tioninitsabilitytogrowduetoanatomicaland/orfunctional
disorders and diseases in the fetoplacental-maternal system
[10]. A satisfactory deﬁnition of IUGR has been suggested by
the American College of Obstetricians and Gynecologists
(ACOG) as “a foetus that fails to reach his potential growth”
[11]. IUGR is usually classiﬁed into symmetric when growth
restriction implies that head circumference, length, and
weight are proportionally SGA; asymmetrical when head cir-
cumferenceisappropriateforgestationalage(AGA),whereas
length and weight are reduced. Symmetric IUGR may de-
pend on a problem during early development and it is asso-
ciated with causes that aﬀect total foetal cell number, includ-
ing chromosomal, genetic, teratogenic, intra-uterine infec-
tions and severe hypertensive aetiologies. Asymmetrical
IUGR is often of a later onset, and occurs whether an under-
nourished foetus directs most of its energy to maintain
growth of vital organs, such as the brain and heart, at the ex-
pense of the liver, muscle, and fat. This type of IUGR is
associated with poor maternal nutrition or late onset exa-
cerbation of maternal vascular disease (preeclampsia, chro-
nic hypertension) and represents an adaptation to an unfa-
vourable intrauterine environment [12].
SGA indicates that a foetus or neonate is below a refer-
ence range for size or weight for a given gestational age. It is
a statistical deﬁnition used for newborns whose birthweight
is less than 10th percentile for that particular gestational age,
referring to the weight of the infant at birth and not to the
growth pattern. Thus, SGA may reﬂect a normal pattern in a
given population, but for deﬁnition often stackable to IUGR
[12, 13].
3. Epidemiology of IUGR
IUGR is an important clinical problem being the most
importantcauseofperinatalmorbidityandmortalitysecond
only to prematurity. IUGR aﬀects approximately 7–15% of
pregnancies [1]. The prevalence is estimated to be approx-
imately 8% in the general population. It has been reported
that52%ofunexplainedstillbirthsareassociatedwithIUGR,
which is also the cause of 10% perinatal mortality. Fur-
thermore, up to 72% of unexplained foetal deaths are asso-
ciatedwithSGAbelowthe10thpercentile.Basedonavailable
data, it has been estimated that between 2.3 and 10% of all
infants are born SGA, although this may still be a gross
underestimate in global terms [3].
4. Risk Factorsof IUGR
During the last ten years, several studies, understanding of
IUGR-associated pathophysiology, have been launched. Act-
ually we know many causes responsible of IUGR, that are
usually summarized in three types of risk factors: maternal,
foetal, and placental factors (Table 1).
The mother’s nutritional status is the major determinant
of IUGR. This includes maternal malnutrition before con-
ception or insuﬃcient nutritional intake during pregnancy.
Furthermore, smoke, substance abuse like alcohol and drug,
maternal hypertension, frequent pregnancies, multiple preg-
nancy, anaemia, and chronic maternal diseases of heart, kid-
n e y s ,l u n g s ,o rl i v e r ,m a yh a v ea na d v e r s ee ﬀect on foetal
weights [4]. Chronic maternal disease alters normal regula-
tion of hormonal activity during pregnancy resulting in in-
creased levels of free circulating corticotropin-releasing hor-
mone (CRH) before its normal increase at term [14].
The foetal abnormalities, such as chromosomal defects,
congenital malformations, chromosomal aberrations, and
infections, can be crucial consequences of IUGR. Intrauter-
ine foetal infections, for example, can limit foetal growth by
directly damaging the foetal brain and neuroendocrine axis
that support foetal growth via insulin-like growth factors
(IGFs) and insulin and by damaging the foetal heart, leading
to diminished cardiac output, poor placental perfusion, and
inadequate nutrient substrate uptake [15].
The placental transport is the major player in foetal nut-
ritionasitdeterminestheavailabilityofoxygenandnutrients
to the foetus. The placenta should be considered as a sensor
between maternal nutritional, metabolic, endocrine and vas-
cular conditions and foetal requirements. Placental insuﬃ-
ciency in IUGR is associated with a limited maternal-foetal
nutrientexchangeasthenormalsupplyofgrowthpromoting
hormones to the foetus (placental lactogen, steroid hormon-
es, insulin-like growth factors) [15, 16].
Vascular placental pathology which is a signiﬁcant lead-
ing factor in IUGR, is often associated with aetiologies of
chronic maternal diseases like hypertension, autoimmune
diseases, obesity and diabetes [17].
The role of oxidative stress and proinﬂammatory cyto-
kines is still under exploration; however, it is suggested that
the oxidative stress could cause vascular dysfunction in the
placenta leading to foetal compromise [18].
5. Consequences of IUGR
Infants exposed to IUGR are not only at risk for an increase
in many perinatal morbidities, but they have been also
associated with adult disease in both human epidemiological
studies and in animal models [19, 20].
The acute neonatal consequences of IUGR are perinatal
asphyxia, hypothermia, hypoglycaemia polycythemia and
other neonatal adaptive problems. The sequelae of perinatal
asphyxia include multiorgan dysfunction neonatal encepha-
lopathy and metabolic acidemia [21].
Numerous epidemiological studies by Barker between
1980s and 1990s have demonstrated a strong association bet-
ween a low birth weight, adult obesity, diabetes, and cardio-
vascular disease [22].
Recently, many other studies have conﬁrmed the cor-
relation between IUGR newborns and the development ofInternational Journal of Endocrinology 3
Table 1: Risk factors in IUGR.
Origin Risk factors
Maternal causes
Medical conditions
(i) Vascular diseases
Chronic hypertension
Preeclampsia early in gestation
Diabetes mellitus
Systemic lupus erythematosus
Chronic kidney disease
Inﬂammatory bowel disease
Severe lung disease
(ii) Infections
Syphilis
Toxoplasmosis
Cytomegalovirus
Rubella virus
Hepatitis B virus
Herpes simplex virus 1 or 2
HIV-1
Helicobacter pylori
Malaria
Social conditions
(i) Malnutrition
Low prepregnancy weight and small maternal size
Poor weight gain during pregnancy, especially in latter half
Nutritional deﬁciencies: protein folic acid, vitamin A, B, C, zinc, calcium
(ii) Drugs use Cigarettes, alcohol, heroin, cocaine
Teratogens, antimetabolites, and therapeutic agents such as trimethadione,
warfarin, and phenytoin
(iii) History
Recent pregnancy and/or high parity
Multiple pregnancy
Prior history of IUGR pregnancy
Residing at altitude over 5,000ft (1,500m)
Fetal Causes
Genetic factors
Race, ethnicity, nationality, sex parity (primiparous, weigh less than subsequent
siblings), genetic disorders (Achondroplasia, Russell-Silver syndrome)
Chromosomal anomalies Chromosomal deletions
Trisomy 13,18, and 21
Congenital malformations Anencephaly, GI atresia, Potter’s syndrome, and pancreatic agenesis
Placental Causes
Placental insuﬃciency Reduced blood ﬂow
Anatomic problems
Multiple infarcts
Aberrant cord insertions
Umbilical vascular thrombosis and hemangiomas
Premature placental separation
Small Placenta4 International Journal of Endocrinology
Foetal
genetics
Intrauterine
environment
IUGR
Insulin-resistant genotype Insulin-resistant phenotype
Insulin resistance
Dyslipidemia DM2 NAFLD Hypertension
MS
Figure 1: Possible hypotheses to explain the association between IUGR and MS. IUGR: intrauterine growth retardation; DM2: type 2 dia-
betes; NAFLD: nonalcoholic fatty liver disease; MS: metabolic syndrome.
theMSlaterinlife,comprisingarterialhypertension,hyperc-
holesterolemia, cardiovascular disease, impaired glucose tol-
erance, and/or DM2, and many other diseases, including
osteoporosis. This association, described in various popula-
tions,isunrelatedtoage,sex,andethnicityandoccursindep-
endently of weight and physical activity [5, 23].
From Barker et al. [2], who was the ﬁrst to introduce the
existing correlationbetweenbirthsizeandlaterdevelopment
ofMSinadultlife,severalauthors[24]showedawidecollec-
tion of data highlighting that subjects born SGA are prone to
centralredistributionofadiposetissueandareathighriskfor
developing insulin resistance, DM2, MS, and cardiovascular
disease.AlthoughthemechanismabletoinduceMSinIUGR
is still unclear in all observed cases, increased insulin resis-
tanceappearedtoplayakeyrole.Twotheorieshavebeenpro-
posed to explain the development of insulin resistance in
IUGR: the ﬁrst is the foetal reprogramming due to thrifty
phenotype hypothesis; the second is the establishment of an
insulin-resistant genotype independently of intrauterine en-
vironment (Figure 1).
According to “thrifty phenotype hypothesis,” maternal
undernutrition during pregnancy modiﬁes the programm-
ing of biochemical mechanisms related to endocrine-meta-
bolic control inducing permanent changes in glucose-insulin
metabolism. These changes include reduced capacity for in-
sulin secretion and insulin resistance which, combined with
the eﬀects of obesity, aging, and physical inactivity, may re-
sultincardiovascularandmetaboliccomplications[25].Fur-
thermore, it has been suggested that, in condition of under-
nutrition, a genotype conferring insulin resistance would be
preferentially selected during evolution because this geno-
type would increase survival among small babies. This phen-
omenon is called the “surviving small baby hypothesis” [26].
This foetal programming of adaptation to an adverse intrau-
terineenvironmentresultsinincreasedsensitivityoftheperi-
pheral tissues to metabolic hormones, such as glucocorti-
coids and insulin, this latter condition enhances survival and
maximizesgrowthandfueldeposition,asthenutritionalpat-
tern improves after birth. So a “thrifty phenotype” postulates
that the intrauterine deprivation programs the fetus to in-
crease appetite and obesity, hypertension, and diabetes [19].
If postnatal nutrient availability is greater than prenatally
predicted, enhanced postnatal growth and fat deposition will
occur. In turn, this increased adiposity will lead to adult
insulin resistance. Certainly, the risk of developing adult MS
is the greatest when poor prenatal growth is coupled with
rapid catch-up growth during childhood [27].
The alternative hypothesis to development of insulin-re-
sistant phenotype in IUGR individuals has suggested that
insulin resistance might be genetically determined indepen-
dently of unfavourable intrauterine environment; as conseq-
uences, thus, also a genetic predisposition to metabolic con-
sequences of IUGR. In particular, Hattersley and Tooke [3]
proposed a “foetal insulin hypothesis,” suggesting the strong
contribution of genetic factors to alter either foetal insulin
secretion or sensitivity of foetal tissues. Polymorphisms or
mutations in genes associated to insulin resistance could
result in impaired foetal growth, low birthweight, and sub-
sequent susceptibility to DM2 and cardiovascular disease in
adult life. In fact, monogenic disorders aﬀect foetal insulin
secretion and resistance causing retarded foetal growth in
utero during the third trimester, just when the insulin in-
crease should act as one of the major growth factors in foe-
tal life. Some monogenic disorders and their eﬀects on insu-
lin and birth weight are reported in Table 2. For example,
mutations in the gene encoding glycolytic enzyme glucoki-
nase have been observed, this mutation results in beta-cell
dysfunction, low-birth-weight and DM2 susceptibility in
childhoodandadulthood[28].However,themonogenicdis-
eases are rare and thus they cannot explain the low birth
weight case normally seen. So it should be clear that both
genetic and environmental factors and their possible interac-
tions may contribute to the development of the MS in later
life [29].
6. Evidence of Association betweenSGA and MS
There are several articles that demonstrated the association
b e t w e e nS G Aa n df e a t u r e so fM S .
Interestingly, there are three relevant clinical trials de-
monstrating a strong association between low birth weight
and insulin resistance. In the ﬁrst study, including 85 SGA
subjects and 23 AGA subjects, the authors found a close link
between insulin secretion/sensitivity, patterns of rapidity,
andlengthofcatch-up-growthprocessduringearlypostnatal
life [30]. In the second study, the authors found that mildlyInternational Journal of Endocrinology 5
Table 2: Monogenic defects associated with insulin-resistant dependent IUGR.
Genetic Defects Disease Pathophysiology
Glucokinase (GK) Heterozigygous mutations Glucokinase deﬁency Low foetal insulin secretion
Insulin promoter factor 1 (IPF1) Homozigygous mutation Pancreatic agenesis Foetal insulin secretion is abolished
Suplphonylurea-receptor1/Kir6
(SUR1/Kir6) Homozigygous mutation Nesidioblastosis Increased insulin secretion
Insulin receptor (IR) Homozigygous mutation Leprechaum syndrome Marked insulin resistance
6q22-q33 Duplication or Paternal isodisomy Transient neonatal diabetes Reduced insulin secretion
impaired insulin sensitivity in 79 prepubertal short children
bornSGAisassociatedwithgrowthhormonetreatment[31].
Finally, the most recent longitudinal study, conducted on 51
individuals, demonstrated that visceral fat excess was, in
postcatch-up SGA children, already present at the age of 6
years and this increment was closely related to the increment
in fasting insulin [32].
The programming is today the most appropriate term to
describe the plasticity of the developing organs, eventually
resulting in permanent changes in structure and/or function.
Therefore, the major programmed defect of metabolism
linking the adverse intrauterine environment is insulin resis-
tance that, in all recent studies, is considered the key factor
forthesimultaneousdevelopmentoftheMSandthelateroc-
currence of DM2 [33].
However, although adults born SGA have a higher inci-
dence of metabolic risk factors (2.3%) than those born AGA
(0.4%), there is no evidence that dyslipidemia occurs more
commonly among children born SGA than in the normal
childhood population [34]. Dyslipidemia, as well as DM2,
might result from the initial development of insulin resis-
tance. One interesting study showed that SGA children with
poor catch-up growth in height may be at the highest risk for
hypercholesterolemia [35]. The real mechanisms are still un-
clear, but some evidence suggests that association between
insulin resistance and dyslipidemia in SGA subjects could be
the consequence of genetic/environmental interactions act-
ing during catch-up growth phase [24].
7. Deﬁnition of NAFLD
The term of NAFLD includes a spectrum of diseases rang-
ing from simple fatty liver to nonalcoholic steatohepatitis
(NASH) with or without ﬁbrosis that may eventually pro-
gress to cirrhosis. Simple fatty liver remains a benign process
inmostaﬀectedpeople,whilethepresenceofliverinﬂamma-
tion, typically observed in NASH, may be the driving force
for the development cirrhosis and hepatocellular carcinoma.
Histological assessment plays an important role in the diag-
nosis and management of paediatric NAFLD; thus, it is im-
portant a carefully discrimination among the diﬀerent histo-
logical features of NAFLD.
The main histological ﬁndings in paediatric NAFLD are
simple steatosis, ballooning, inﬂammation and ﬁbrosis, but
also other liver lesions may be present. Despite the increased
number of studies directed to search less invasive diagnostics
methods, liver biopsy evaluation continues to be considered
the “gold standard” in establishing the diagnosis as well the
severity of NAFLD. However, liver biopsy presents several
limitations including high risk, high costs, “sampling errors”
and the interobserver variations in the histopathologic as-
sessment [36–38].
8. Epidemiology of NAFLD
NAFLD is an increasingly recognized cause of liver disease
worldwide. The incidence and the true prevalence of pae-
diatric NAFLD remains unknown due to the lack of prospec-
tive studies. Population-based studies might provide more
accurate ﬁgures, but few such studies have been reported to
date. A high prevalence rate between 2% and 80% of NAFLD
hasbeenreportedinNorthandSouthAmerica,Europe,Aus-
tralia, and Asia [38]. The high variability in prevalence data
from diﬀerent geographical areas not only may depend on
the type of test but it may also be inﬂuenced by the age, sex
andethnicity-collectedpopulation.Theimportanceofmeta-
bolic factors has been also demonstrated by several evidences
suggestingthatNASHmightbeconsideredthehepaticmani-
festation of the MS. In particular, DM2 is associated both
with obesity, NAFLD, and development of progressive liver
ﬁbrosis.Dyslipidemia(i.e.,hypertriglyceridemiaand/orhyp-
ercholesterolemia), which is frequently associated with both
obesity and DM2, has been also reported in 20–80% of pa-
tients with NASH. Interestingly, also hyperglycemia is asso-
ciated with NASH; in fact, the prevalence of NAFLD rises in
hyperglycemic patients, and insulin resistance is more severe
in individuals with NASH in versus steatosis [38, 39].
9. Etiopathogenesis of NAFLD
The etiopathogenesis of NAFLD has been long disputed.
Mostauthorsconsiderplausiblethetheoryof“multiplehits.”
According to this theory, liver fat accumulation and insulin
resistance, which are the suggested “primary hits,” may lead
to simple steatosis and making fatty liver more vulnerable to
possible “secondary hits” which may be involved in the pro-
gression to NASH (Figure 2). “Secondary hits” include oxi-
dative stress, mitochondrial dysfunction, and imbalance of
production/release of hormones derived from adipose tissue
(adipocytokines) [40, 41]. More recently, also a gut/liver axis
hypothesis has been included. This suggests that bacterial
endotoxins of intestinal origin and the related mechanisms
of innate immune response may act as possible inductors of
necroinﬂammatory lesions in the progression of steatosis to6 International Journal of Endocrinology
Environmental
factors
Primary hits Secondary hits
- Insulin resistance
- Fat accumulation
- Mitochondrial dysfunctions
- Gut-liver axis
- Oxidative stress
Fatty liver
NASH Genetic
factors
- Adipocytokine imbalance
Figure 2: Simpliﬁed representation of NASH pathogenesis. NASH, nonalcoholic steatohepatitis.
NASH and severe ﬁbrosis [42]. This is at present the most
accredited pathogenetic model (Figure 2), even though, the
complicated molecular network of interactions that leads to
NAFLD/NASHoftenconfusescausesandeﬀects.Despitethis
apparent confusion, all today theories consider the insulin
resistance the major actor in the development of paediatric
NAFLD [43]. Although causative mechanism which links
insulinresistanceandNAFLDisstillunderinvestigation,two
main hypotheses are formulated. In genetically predisposed
individuals, environmental and nutritional factors interact
withthriftygenesfavouringtheoccurrenceofwholebodyin-
sulinresistance,and,inturn,theinappropriateaccumulation
of fats in muscle and liver, or causing fat deposition and con-
sequent insulin resistance ﬁrst in the liver and just in seq-
uence at the peripheral sites [44].
10.AssociationbetweenSGAanNAFLD and
Possible Therapeutic Management
A number of recent studies shed light on the relationship
between IUGR, rapid weight gain after birth, and increased
risk of MS in adulthood [45–47]. These studies highlight the
fact that the nutrient deﬁciency during fetal life can induce,
consequently to an adaptive mechanism, an upregulation of
the expression of insulin receptor. So after birth, the relevant
activation of insulin signalling pathway could lead to a rapid
weight gain [45].
Interestingly, Rueda-Clausen and colleagues observed
that rats with hypoxia-induced IUGR and fed with high-fat
diet were more susceptible to develop metabolic derange-
ment of lipid homeostasis. This in vivo model of IUGR also
induced insulin resistance, impaired glucose tolerance acco-
mpanied by augmented protein kinase C phosphorylation,
both in the liver and in the skeletal muscle [46].
In another recent study, Magee and coworkers showed
how IUGR might be associated with not only obesity and
lipid abnormalities, but also fatty liver and inﬂammation. In
this study, IUGR oﬀsprings displayed hepatic downregula-
tion of peroxisome proliferator-activated receptor (PPAR)α
and γ and upregulation of sterol regulatory element-binding
protein-1 and fatty acid synthase [47]. All these proteins are
involved in the regulation of lipid metabolism and lipid-
associated inﬂammatory response strongly and are often
associated to NAFLD pathogenesis [40].
Finally,onlyonereportdescribestheassociationbetween
low birthweight and NAFLD in humans [7]. In this study,
Nobili et al. demonstrated the association of paediatric
NAFLD with IUGR, independently of insulin resistance. In
90 Italian children with biopsy-proven NAFLD, the preva-
lence of SGA with NAFLD was approximately fourfold high-
er if compared to the average SGA prevalence of children
admitted to our hospital. As already described, insulin resis-
tance may represent the link between metabolic/NAFLD and
IUGR. Consequently, IUGR and especially low birth weight
might represent an important risk factor for paediatric
NAFLD.
Therapeutic approaches in NAFLD try to limit the pro-
gression from fatty liver to steatohepatitis and to reverse his-
tological features of necroinﬂammation and ﬁbrosis. Chang-
es in lifestyle represent valuable means in both prevention
and treatment of fatty liver and NASH. Weight loss and
weight control can be the ﬁrst line to prevent the onset of
fatty liver, being overweight/obesity major contributing fac-
tors to fatty inﬁltration of the liver. In fact, diet and physi-
cal exercise are currently considered the cornerstone for pae-
diatric NAFLD [38].
Singhal et al. [9] suggests that restricting postnatal cat-
chup after prematurity will avoid later metabolic abnormali-
ties. In addition, it has been suggested that the consumption
of human milk has many beneﬁts and an adequate breast-
feeding protects against the development of obesity and
NAFLD in childhood and adults [48]. Thus, even though
it remains to be determined what are the mechanisms and
the speciﬁc diﬀerences in composition between human milkInternational Journal of Endocrinology 7
and commercial formula able to produce metabolic distur-
bance,andhowbreastfeedingmayexertitspreventiveaction,
it is clear that certainly caution should be used in nutrition
program for IUGR individuals. In particular, catch-up
growth should be restricted and also an accurate research of
the “the best milk formula” should be made to prevent some
features of MS.
11. Conclusions
In this paper, we overviewed principal characteristics of
IUGR and the relationship between birth weight and some
main features of MS, especially NAFLD.
In addition, we demonstrated that several evidence exists
on the associations between low birth weight and some fea-
tures of metabolic syndrome in later life. It appears that the
period of maximal foetal growth and the later period of
catch-up growth speciﬁcally inﬂuence insulin resistance and
developmentofMSanditscomorbidities.However,thereare
still signiﬁcant gaps in the knowledge of mechanisms gener-
ating metabolic proﬁle and outcome in IUGR individuals.
Ascatch-upgrowthandnutritionareinvolvedindevelop-
ment of metabolic abnormalities in SGA subjects, it may be
possible to alter early metabolic programming by improving
speciﬁc macro- or micronutrient deﬁciencies during the
neonatal period.
In conclusion, a routine health surveillance of all adults
born SGA should be recommended in normal clinical prac-
tice, and an adequate lifestyle program (appropriate diet and
exercise) might help to prevent MS and NAFLD also in these
subjects with high risk for both diseases.
Conﬂict of Interests
The authors declared that they have no conﬂict of interests.
References
[1] World Health Organization, “WHO report: reducing risks,
promoting healthy life,” Geneva, Switzerland, World Health
Organization, 2002.
[ 2 ]D .J .P .B a r k e r ,C .N .H a l e s ,C .H .D .F a l l ,C .O s m o n d ,K .
Phipps, and P. M. S. Clark, “Type 2 (non-insulin-dependent)
diabetes mellitus, hypertension and hyperlipidaemia (syn-
drome X): relation to reduced fetal growth,” Diabetologia, vol.
36, no. 1, pp. 62–67, 1993.
[3] A. T. Hattersley and J. E. Tooke, “The fetal insulin hypothesis:
an alternative explanation of the association of low birth-
weight with diabetes and vascular disease,” Lancet, vol. 353,
no. 9166, pp. 1789–1792, 1999.
[4] K. Haram, E. Svendsen, and O. Myking, “Growth restriction:
etiology, maternal and neonatal outcome. A review,” Current
Women’s Health Reviews, vol. 3, no. 3, pp. 145–160, 2007.
[5] G. Valsamakis, C. Kanaka-Gantenbein, A. Malamitsi-Puchner,
and G. Mastorakos, “Causes of intrauterine growth restriction
and the postnatal development of the metabolic syndrome,”
AnnalsoftheNewYorkAcademyofSciences,vol. 1092, pp. 138–
147, 2006.
[6] A. Alisi, S. Cianfarani, M. Manco, C. Agostoni, and V. Nobili,
“Non-alcoholic fatty liver disease and metabolic syndrome
in adolescents: pathogenetic role of genetic background and
intrauterine environment,” Annals of Medicine. In press.
[7] V. Nobili, A. Alisi, N. Panera, and C. Agostoni, “Low birth
weight and catch-up-growth associated with metabolic syn-
drome: a ten year systematic review,” Pediatric Endocrinology
Reviews, vol. 6, no. 2, pp. 241–247, 2008.
[8] I. Brandt, E. J. Sticker, and M. J. Lentze, “Catch-up growth
of head circumference of very low birth weight, small for
gestational age preterm infants and mental development to
adulthood,” Journal of Pediatrics, vol. 142, no. 5, pp. 463–468,
2003.
[9] A. Singhal, M. Fewtrell, T. J. Cole, and A. Lucas, “Low
nutrient intake and early growth for later insulin resistance
in adolescents born preterm,” Lancet, vol. 361, no. 9363, pp.
1089–1097, 2003.
[10] Z. Ergaz, M. Avgil, and A. Ornoy, “Intrauterine growth
restriction - Etiology and consequences: what do we know
about the human situation and experimental animal models?”
Reproductive Toxicology, vol. 20, no. 3, pp. 301–322, 2005.
[11] G. P. Mandruzzato, “Intrauterine growth restriction (IUGR):
guidelines for deﬁnition, recognition and management,”
Archives of Perinatal Medicine, vol. 14, pp. 7–8, 2008.
[12] A. K. Deorari, R. Agarwal, and V. K. Paul, “Management of
infants with intra-uterine growth restriction,” Indian Journal
of Pediatrics, vol. 75, no. 2, pp. 171–174, 2008.
[ 1 3 ]T .N .L e u n g ,C .W .K .L a m ,K .F .T o ,a n dC .J .H a i n e s ,
“Changes in concentrations of lipoprotein (a) and other lipids
and lipoproteins in pregnancies complicated by pregnancy-
induced hypertension or intrauterine growth retardation,”
Hypertension in Pregnancy, vol. 17, no. 2, pp. 157–168, 1998.
[14] M.Weinstock,“Thepotentialinﬂuenceofmaternalstresshor-
mones on development and mental health of the oﬀspring,”
Brain, Behavior, and Immunity, vol. 19, no. 4, pp. 296–308,
2005.
[15] N. Hendrix and V. Berghella, “Non-Placental Causes of
Intrauterine Growth Restriction,” Seminars in Perinatology,
vol. 32, no. 3, pp. 161–165, 2008.
[16] H. D. McIntyre, R. Serek, D. I. Crane et al., “Placental
growth hormone (GH), GH-binding protein, and insulin-like
growth factor axis in normal, growth-retarded, and diabetic
pregnancies:correlationswithfetalgrowth,”JournalofClinical
Endocrinology and Metabolism, vol. 85, no. 3, pp. 1143–1150,
2000.
[17] I.CetinandG.Alvino,“Intrauterinegrowthrestriction:impli-
cations for placental metabolism and transport. A review,”
Placenta, vol. 30, pp. 77–82, 2009.
[18] L. Myatt, W. Kossenjans, R. Sahay, A. Eis, and D. Brockman,
“Oxidative stress causes vascular dysfunction in the placenta,”
Journal of Maternal-Fetal and Neonatal Medicine, vol. 9, no. 1,
pp. 79–82, 2000.
[19] M. G. Ross and M. H. Beall, “Adult sequelae of intrauterine
growth restriction,” Seminars in Perinatology, vol. 32, no. 3,
pp. 213–218, 2008.
[20] P. D. Gluckman, M. A. Hanson, and C. Pinal, “The develop-
mental origins of adult disease,” Maternal and Child Nutrition,
vol. 1, no. 3, pp. 130–141, 2005.
[21] D. D. Mcintire, S. L. Bloom, B. M. Casey, and K. J. Leveno,
“Birth weight in relation to morbidity and mortality among
newborn infants,” New England Journal of Medicine, vol. 340,
no. 16, pp. 1234–1238, 1999.
[22] D.J.P.Barker,“Maternalnutrition,fetalnutrition,anddisease
in later life,” Nutrition, vol. 13, no. 9, pp. 807–813, 1997.
[23] D. D. Briana and A. Malamitsi-Puchner, “Intrauterine growth
restriction and adult disease: the role of adipocytokines,”8 International Journal of Endocrinology
European Journal of Endocrinology, vol. 160, no. 3, pp. 337–
347, 2009.
[24] C. L´ evy-Marchal and P. Czernichow, “Small for gestational age
and the metabolic syndrome: which mechanism is suggested
by epidemiological and clinical studies?” Hormone Research,
vol. 65, no. 3, pp. 123–130, 2006.
[25] C. N. Hales and D. J. P. Barker, “The thrifty phenotype hypo-
thesis,” British Medical Bulletin, vol. 60, pp. 5–20, 2001.
[ 2 6 ]L .N a i r ,M .K .N a i r ,a n dD .S .C h a c k o ,“ M a r k e r so ff e t a lo n s e t
adult diseases,” Indian pediatrics, vol. 46, pp. s48–s54, 2009.
[27] D. Jaquet, A. Gaboriau, P. Czernichow, and C. Levy-Marchal,
“Insulin resistance early in adulthood in subjects born with
intrauterine growth retardation,” Journal of Clinical Endocri–
nology and Metabolism, vol. 85, no. 4, pp. 1401–1406, 2000.
[28] A. T. Hattersley, F. Beards, E. Ballantyne, M. Appleton, R. Har-
vey, and S. Ellard, “Mutations in the glucokinase gene of the
fetus result in reduced birth weight,” Nature Genetics, vol. 19,
no. 3, pp. 268–270, 1998.
[29] D. Jaquet, J. Leger, P. Czernichow, and C. Levy-Marchal, “The
eﬀect of in-utero undernutrition on the insulin resistance syn-
drome,” Current diabetes reports, vol. 2, no. 1, pp. 77–82, 2002.
[30] N. Soto, R. A. Bazaes, V. Pe˜ na et al., “Insulin sensitivity and
s e c r e t i o na r er e l a t e dt oc a t c h - u pg r o w t hi ns m a l l - f o r - g e s t a -
tional-age infants at age 1 year: results from a prospective co-
hort,” Journal of Clinical Endocrinology and Metabolism, vol.
88, no. 8, pp. 3645–3650, 2003.
[ 3 1 ]A .C .S .H o k k e n - K o e l e g a ,W .J .D eW a a l ,T .C .J .S a s ,Y .V a n
Pareren, and N. J. T. Arends, “Small for gestational age (SGA):
endocrine and metabolic consequences and eﬀects of growth
hormone treatment,” Journal of Pediatric Endocrinology and
Metabolism, vol. 17, no. 3, pp. 463–469, 2004.
[32] L. Ib´ a˜ nez, L. Su´ arez, A. Lopez-Bermejo, M. D´ ıaz, C. Valls, and
F. De Zegher, “Early development of visceral fat excess after
spontaneous catch-up growth in children with low birth
weight,” Journal of Clinical Endocrinology and Metabolism, vol.
93, no. 3, pp. 925–928, 2008.
[33] A. Vaag, C. Bjørn Jensen, P. Poulsen et al., “Metabolic aspects
of insulin resistance in individuals born small for gestational
age,” Hormone Research, vol. 65, no. 3, pp. 137–143, 2006.
[34] D. Jaquet, S. Deghmoun, D. Chevenne, D. Collin, P. Czerni-
chow, and C. L´ evy-Marchal, “Dynamic change in adiposity
from fetal to postnatal life is involved in the metabolic syn-
drome associated with reduced fetal growth,” Diabetologia,
vol. 48, no. 5, pp. 849–855, 2005.
[35] S. Tenhola, A. Martikainen, E. Rahiala, E. Herrg˚ Ard, P.
Halonen,andR.Voutilainen,“Serumlipidconcentrationsand
growth characteristics in 12-year-old children born small for
gestational age,” Pediatric Research, vol. 48, no. 5, pp. 623–628,
2000.
[36] E. M. Brunt, “Pathology of fatty liver disease,” Modern Patho-
logy, vol. 20, no. 1, pp. S40–S48, 2007.
[37] M. M. Yeh and E. M. Brunt, “Pathology of nonalcoholic fatty
liver disease,” American Journal of Clinical Pathology, vol. 128,
no. 5, pp. 837–847, 2007.
[38] A. Alisi, M. Manco, A. Vania, and V. Nobili, “Pediatric non-
alcoholic fatty liver disease in 2009,” Journal of Pediatrics, vol.
155, no. 4, pp. 469–474, 2009.
[39] J.-F. Fu, H.-B. Shi, L.-R. Liu et al., “Non-alcoholic fatty liver
disease: an early mediator predicting metabolic syndrome in
obese children?” World Journal of Gastroenterology, vol. 17, no.
6, pp. 735–742, 2011.
[40] H. Tilg and A. R. Moschen, “Insulin resistance, inﬂammation,
and non-alcoholic fatty liver disease,” Trends in Endocrinology
and Metabolism, vol. 19, no. 10, pp. 371–379, 2008.
[41] A. Alisi, M. Locatelli, and V. Nobili, “Nonalcoholic fatty liver
disease in children,” Current Opinion in Clinical Nutrition and
Metabolic Care, vol. 13, no. 4, pp. 397–402, 2010.
[42] G. Baﬀy, “Kupﬀer cells in non-alcoholic fatty liver disease: the
emerging view,” Journal of Hepatology, vol. 51, no. 1, pp. 212–
223, 2009.
[43] N. Mendez-Sanchez, M. Arrese, D. Zamora-Vald´ es, and M.
Uribe, “Current concepts in the pathogenesis of nonalcoholic
fatty liver disease,” Liver International, vol. 27, no. 4, pp. 423–
433, 2007.
[44] E. W. Kraegen and G. J. Cooney, “Free fatty acids and skeletal
muscle insulin resistance,” Current Opinion in Lipidology, vol.
19, no. 3, pp. 235–241, 2008.
[45] J. L. Morrison, J. A. Duﬃeld, B. S. Muhlhausler, S. Gentili,
andI.C.McMillen,“Fetalgrowthrestriction,catch-upgrowth
and the early origins of insulin resistance and visceral obesity,”
Pediatric Nephrology, vol. 25, no. 4, pp. 669–677, 2010.
[46] C. F. Rueda-Clausen et al., “Hypoxia-induced intrauterine
growth restriction increases the susceptibility of rats to high-
fat diet-induced metabolic syndrome,” Diabetes, vol. 60, pp.
507–516, 2011.
[47] T. R. Magee, G. Han, B. Cherian, O. Khorram, M. G. Ross,
and M. Desai, “Down-regulation of transcription factor per-
oxisome proliferator-activated receptor in programmed hep-
atic lipid dysregulation and inﬂammation in intrauterine
growth-restricted oﬀspring,” American Journal of Obstetrics
and Gynecology, vol. 199, no. 3, pp. 271–e1, 2008.
[48] V. Nobili, G. Bedogni, A. Alisi et al., “A protective eﬀect of
breastfeeding on the progression of non-alcoholic fatty liver
disease,” Archives of Disease in Childhood, vol. 94, no. 10, pp.
801–805, 2009.